Advertisement
Screener

Seres Therapeutics, Inc. (MCRB) Interest Income (Expense), Nonoperating, Net

2.8 / 5 stars · 68/120 Roast Me

Seres Therapeutics, Inc. Interest Income (Expense), Nonoperating, Net

Seres Therapeutics, Inc. (MCRB) reported Interest Income (Expense), Nonoperating, Net of $335.00 thousand for the 3-month period ending 2019-09-30, per its 10-Q filed 2019-11-05.

Discontinued › Income Statement › Other Income

us-gaap:InterestIncomeExpenseNonoperatingNet · last filed 2019-11-05

  • Seres Therapeutics, Inc. interest income (expense), nonoperating, net for the quarter ending 2019-09-30 was $335.00K, a 27.86% increase year-over-year.
  • Seres Therapeutics, Inc. interest income (expense), nonoperating, net for the quarter ending 2019-06-30 was $189.00K, a 45.85% decline year-over-year.
  • Seres Therapeutics, Inc. interest income (expense), nonoperating, net for the quarter ending 2019-03-31 was $220.00K, a 36.60% decline year-over-year.
  • Seres Therapeutics, Inc. interest income (expense), nonoperating, net for the quarter ending 2018-12-31 was $214.00K.
  • Seres Therapeutics, Inc. interest income (expense), nonoperating, net for fiscal 2018 was $1.17M, a 26.29% decline from fiscal 2017.
  • Seres Therapeutics, Inc. interest income (expense), nonoperating, net for fiscal 2017 was $1.59M, a 26.19% increase from fiscal 2016.
  • Seres Therapeutics, Inc. interest income (expense), nonoperating, net for fiscal 2016 was $1.26M.
Period endInterest Income (Expense), Nonoperating, Net 3 monthInterest Income (Expense), Nonoperating, Net 6 monthInterest Income (Expense), Nonoperating, Net 9 monthInterest Income (Expense), Nonoperating, Net 12 month
2019-09-30$335.00K
10-Q · filed 2019-11-05
$524.00K
derived: sum of 2 quarters · filed 2019-11-05
$744.00K
10-Q · filed 2019-11-05
$958.00K
derived: sum of 4 quarters · filed 2019-11-05
2019-06-30$189.00K
10-Q · filed 2019-08-06
$409.00K
10-Q · filed 2019-08-06
$623.00K
derived: sum of 3 quarters · filed 2019-08-06
$885.00K
derived: sum of 4 quarters · filed 2019-11-05
2019-03-31$220.00K
10-Q · filed 2019-05-02
$434.00K
derived: sum of 2 quarters · filed 2019-05-02
$696.00K
derived: sum of 3 quarters · filed 2019-11-05
$1.04M
derived: sum of 4 quarters · filed 2019-11-05
2018-12-31$214.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-06
$476.00K
derived: sum of 2 quarters · filed 2019-11-05
$825.00K
derived: sum of 3 quarters · filed 2019-11-05
$1.17M
10-K · filed 2019-03-06
2018-09-30$262.00K
10-Q · filed 2019-11-05
$611.00K
derived: sum of 2 quarters · filed 2019-11-05
$958.00K
10-Q · filed 2019-11-05
2018-06-30$349.00K
10-Q · filed 2019-08-06
$696.00K
10-Q · filed 2019-08-06
2018-03-31$347.00K
10-Q · filed 2019-05-02
2017-12-31$1.59M
10-K · filed 2019-03-06
2016-12-31$1.26M
10-K · filed 2019-03-06

Similar stocks

Stock NameCountryMarket CapPE Ratio
MIRA PHARMACEUTICALS, INC. (MIRA)United States$0.036B-4.30
BriaCell Therapeutics Corp. (BCTX)$0.037B
PMGC Holdings Inc. (ELAB)United States$0.037B
FILANA THERAPEUTICS, INC. (FLNA)United States$0.038B-1.05
Actinium Pharmaceuticals, Inc. (ATNM)United States$0.038B2.73
ROCKWELL MEDICAL, INC. (RMTI)United States$0.035B
Celularity Inc (CELU)United States$0.038B-0.34
CervoMed Inc. (CRVO)United States$0.038B-1.39
Context Therapeutics Inc. (CNTX)United States$0.034B-1.10
Edesa Biotech, Inc. (EDSA)Canada$0.039B